8-K: Incannex Completes Dosing in Phase 2 PsiGAD Trial for Anxiety, Topline Results Expected Soon

Incannex Healthcare has completed dosing and treatment for all 72 participants in its Phase 2 PsiGAD clinical trial assessing psilocybin-assisted psychotherapy for generalized anxiety disorder, with topline results anticipated in the current quarter.

Summary

• Incannex Healthcare has finished dosing and treatment for all 72 participants in the Phase 2 PsiGAD-1 clinical trial.
• The trial is evaluating a 7-week psilocybin-assisted psychotherapy program for generalized anxiety disorder (GAD).
• The primary goal is to determine if the psilocybin treatment is more effective than a placebo in reducing GAD symptoms.
• The study uses the Hamilton Anxiety Rating Scale (HAM-A) to measure changes in anxiety levels.
• The trial was conducted at Monash University in Melbourne, Australia, and involved screening 975 people.
• There were 174 psychedelic dosing sessions conducted as part of the trial.
• Topline results from the trial are expected within the current Q1 2024.
• An FDA IND application is being prepared, with the process starting in August 2023.
• An independent documentary about the Monash Clinical Psychedelic Lab and the PsiGAD research program will be released in late February 2024.

Sentiment

Score: 7

Explanation: The document is positive due to the completion of the trial and the anticipation of results, but there is still uncertainty about the outcome and regulatory approval.

Positives

• The completion of dosing and treatment in the Phase 2 PsiGAD-1 trial is a significant milestone.
• The trial has a robust design, being randomized, triple-blind, and placebo-controlled.
• The company is actively preparing an FDA IND application, indicating progress towards regulatory approval.
• The documentary release will increase awareness of mental health and psychedelic therapies.
• An interim analysis predicted a greater than 85% chance of statistically significant benefit for the psilocybin treatment arm.

Risks

• The trial results are not yet available, and there is a risk that the topline results may not be positive.
• The FDA IND application process is subject to regulatory review and approval, which is not guaranteed.
• The documentary release may not have the desired impact on public awareness or acceptance of psychedelic therapies.

Future Outlook

The company anticipates topline results from the PsiGAD-1 clinical trial in the current Q1 2024 and plans to submit an FDA IND application soon after.

Management Comments

• Joel Latham, Chief Executive Officer and President of Incannex, stated that they are delighted to have completed all PsiGAD-1 treatments and are working towards finalizing an FDA IND application.

Industry Context

The announcement is relevant to the growing interest in psychedelic therapies for mental health conditions. It positions Incannex as a key player in the development of psilocybin-based treatments for anxiety disorders.

Comparison to Industry Standards

• The PsiGAD-1 trial is one of the larger clinical trials of its kind, with 72 participants, compared to some smaller pilot studies in the psychedelic space.
• The use of a randomized, triple-blind, active-placebo-controlled design is consistent with high standards for clinical trials in the pharmaceutical industry.
• The company's focus on obtaining FDA approval aligns with the industry's move towards regulatory acceptance of psychedelic therapies.

Stakeholder Impact

• Shareholders may see a positive impact if the trial results are favorable and the FDA IND application is successful.
• Patients with generalized anxiety disorder may benefit from a new treatment option if the therapy is approved.
• The research community will gain valuable insights from the trial results and the documentary.

Next Steps

• The company will analyze the data from the PsiGAD-1 clinical trial.
• Incannex will finalize and submit an FDA IND application.
• The company will await the release of the documentary on the Monash Clinical Psychedelic Lab.

Key Dates

Keywords

psilocybin, anxiety, clinical trial, psychedelic therapy, FDA IND, generalized anxiety disorder, mental health, pharmacotherapy, Incannex, PsiGAD